Thalidomide-linker 4

Background Introduction

Thalidomide-linker 4 is a specialized E3 ligase ligand-linker conjugate designed to facilitate targeted protein degradation via PROTAC (Proteolysis Targeting Chimera) technology. As a derivative of thalidomide, this compound harnesses cereblon (CRBN) as the E3 ligase recruiter, making it a popular choice for constructing effective and selective PROTAC molecules. The addition of a functionalized linker provides a versatile handle for conjugation to various target protein ligands, enabling rapid prototyping and optimization of bifunctional molecules for research and development.

Mechanism

Thalidomide-linker 4 operates through a bifunctional mechanism central to PROTAC technology. The thalidomide-based moiety binds specifically to the CRBN E3 ubiquitin ligase, while the customizable linker serves as a bridge to conjugate the molecule to a ligand that binds the protein of interest. Once the PROTAC molecule is formed and introduced into a cellular system, it simultaneously brings the CRBN E3 ligase in close proximity to the target protein. This induced proximity triggers the ubiquitination and subsequent proteasomal degradation of the targeted protein, enabling selective and efficient knockdown at the post-translational level.

Applications

Thalidomide-linker 4 is widely used in the development and optimization of PROTACs for both basic research and drug discovery. Its applications include: (1) Creation of targeted protein degraders for oncology, immunology, and neurodegenerative disease research; (2) Investigation of degradation mechanisms and E3 ligase selectivity in cellular environments; (3) Development of novel therapeutic candidates by enabling rapid generation of bifunctional molecules; and (4) Structure-activity relationship (SAR) studies to fine-tune linker length, stability, and selectivity of PROTAC compounds. This versatile intermediate is ideal for scientists seeking to accelerate the design and synthesis of next-generation protein degraders.

• Thalidomide-linker 4 delivers reliable CRBN E3 ligase recruitment, enabling targeted protein degradation in PROTAC applications.
• Versatile linker structure supports seamless conjugation with diverse warheads, optimizing PROTAC design flexibility.

Thalidomide-linker 4 is a versatile E3 Ligase Ligand-Linker Conjugate designed for use in PROTACs, facilitating targeted protein degradation by linking a thalidomide-based ligand to a protein of interest. The following provides a detailed description of this molecule, emphasizing its linker, ligand, and compatibility with target protein ligands.

Linker: This molecule features a medium-length, flexible linker that allows for optimal spatial orientation between the ligand and the target protein. The linker is non-cleavable, ensuring stability of the conjugate throughout the degradation process.

Ligand: The ligand in this molecule is a thalidomide derivative, known for its high affinity and specificity towards the cereblon E3 ubiquitin ligase. Its structural characteristics enhance binding efficiency, making it an effective component of PROTACs.

Reactive Site: The reactive site on this molecule is designed to couple efficiently with target protein ligands through amide bond formation. Recommended reaction types include amidation and esterification, which facilitate stable conjugation under mild conditions.

Recommended Target Protein Ligand: The compatible warhead for this molecule is typically an electrophilic moiety, such as a carbonyl-containing group. This offers the advantage of forming covalent bonds with nucleophilic residues on the target protein, enhancing selectivity and potency. Such warheads are ideal for applications requiring precise protein degradation in cellular studies.